Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer.
de Miguel-Perez D, Ortega FG, Tejada RG, Martínez-Única A, Peterson CB, Russo A, Gunasekaran M, Cardona AF, Amezcua V, Lorente JA, Expósito Hernández J, Rolfo C, Serrano MJ. de Miguel-Perez D, et al. Among authors: peterson cb. Biomark Res. 2023 Nov 15;11(1):98. doi: 10.1186/s40364-023-00544-y. Biomark Res. 2023. PMID: 37968730 Free PMC article.
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, Mamindla P, Lara-Mejia L, Peterson CB, Er ME, Peddagangireddy V, Buemi F, Cooper B, Manca P, Lapidus RG, Hsia RC, Cardona AF, Naing A, Kaushal S, Hirsch FR, Mack PC, Serrano MJ, Adamo V, Colen RR, Rolfo C. de Miguel-Perez D, et al. Among authors: peterson cb. J Exp Clin Cancer Res. 2022 Jun 2;41(1):186. doi: 10.1186/s13046-022-02379-1. J Exp Clin Cancer Res. 2022. PMID: 35650597 Free PMC article.
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.
Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Colen RR, et al. Among authors: peterson cb. J Immunother Cancer. 2021 Apr;9(4):e001752. doi: 10.1136/jitc-2020-001752. J Immunother Cancer. 2021. PMID: 33849924 Free PMC article.
Author response to Cunha et al.
Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Colen RR, et al. Among authors: peterson cb. J Immunother Cancer. 2021 Jul;9(7):e003299. doi: 10.1136/jitc-2021-003299. J Immunother Cancer. 2021. PMID: 34315823 Free PMC article.
Using FFF Beams to Improve the Therapeutic Ratio of Lung SBRT.
Vassiliev ON, Peterson CB, Chang JY, Mohan R. Vassiliev ON, et al. Among authors: peterson cb. J Radiother Pract. 2021 Dec;20(4):419-425. doi: 10.1017/s1460396920000576. Epub 2020 Jul 30. J Radiother Pract. 2021. PMID: 35330584 Free PMC article.
Tsyn-Seq: a T-cell Synapse-Based Antigen Identification Platform.
Jin Y, Miyama T, Brown A, Hayase T, Song X, Singh AK, Huang L, Flores II, McDaniel LK, Glover I, Halsey TM, Prasad R, Chapa V, Ahmed S, Zhang J, Rai K, Peterson CB, Lizee G, Karmouch J, Hayase E, Molldrem JJ, Chang CC, Tsai WB, Jenq RR. Jin Y, et al. Among authors: peterson cb. Cancer Immunol Res. 2024 May 2;12(5):530-543. doi: 10.1158/2326-6066.CIR-23-0467. Cancer Immunol Res. 2024. PMID: 38363296
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.
Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Strati P, et al. Among authors: peterson cb. Blood Adv. 2019 May 14;3(9):1533-1539. doi: 10.1182/bloodadvances.2019031336. Blood Adv. 2019. PMID: 31076409 Free PMC article. Clinical Trial.
415 results